Isatuximab 是一种单克隆抗体,靶向跨膜受体和胞外酶 CD38,一种在血液系统恶性细胞,包括多发性骨髓瘤中高度表达的蛋白。Isatuximab 通过多种生物学机制具有抗肿瘤活性,包括抗体依赖性细胞介导的细胞毒性、补体依赖性细胞毒性、抗体依赖性细胞吞噬作用和无交联直接诱导细胞凋亡 (apoptosis)。Isatuximab 还直接抑制 CD38 胞外酶活性,这与许多细胞功能有关。
Isatuximab is a monoclonal antibody that targets the transmembrane receptor and the extracellular enzyme CD38, a protein highly expressed in malignant cells of the blood system, including multiple myeloma. Isatuximab has antitumor activity through a variety of biological mechanisms, including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cytophagocytosis, and direct induction of apoptosis without crosslinking. Isatuximab also directly inhibits CD38 extracellular enzyme activity, which is associated with many cellular functions.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg